InvestSMART

Bio-Gene Technology Ltd (ASX:BGT)

ALERT: Price-sensitive ASX Announcement for BGT
Current share price for BGT : $0.017 -0.014 (-45.16%)+
Announcement
Release
30 Jan 2026 8:24AM
Price at Release
$0.031
Full Release
download
Summary
Bio-Gene Technology Limited, an Australian agtech company, has demonstrated significant progress in its Flavocide® and Qcide® platforms. The company has moved into advanced phases of regulatory and commercial activities, with Flavocide® focusing on regulatory-enabling safety studies and Qcide® expanding its market access after receiving OMRI approval. The company is also collaborating on US Department of Defense-funded projects to create new insect-control solutions. The quarterly cash flow report indicates a net cash outflow due to operational expenditures but includes a significant R&D tax incentive refund.
Key Points
  • Bio-Gene Technology Limited (ASX:BGT) is advancing its Flavocide® and Qcide® platforms with regulatory, product development, and commercialization activities.
  • Flavocide® development includes regulatory-enabling safety studies and formulation development with commercial partners to expand its efficacy data.
  • Qcide® has received approval from the US Organic Materials Review Institute (OMRI) for listing as a Botanical Pesticide, supporting its use in organic agriculture.
  • The company is involved in two US Department of Defense-funded programs to develop insect-control solutions with A$3.0 million grant funding.
  • Financial reports show operating cash flows with a net cash decrease attributed to operational expenses.
  • The company received a research and development tax incentive of $519,500 from the Australian Taxation Office related to their 2025 financial year R&D expenditure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.